-
Lay off 156 people!
Time of Update: 2021-08-07
CompilationTom LeeRecently, according to a warning notice sent by GlaxoSmithKline (GSK) to the Tennessee Department of Labor and Workforce Development, the company has decided to close its manufacturing plant in Memphis, Tennessee, and 156 employees will face unemployment .
-
Several executives of Bikang Pharmaceutical resign
Time of Update: 2021-08-07
On July 7, Yanan Bikang Pharmaceutical issued an announcement stating that the board of directors had recently received written resignation reports from Chairman Gu Xiaojia, Vice Chairman Li Jingkun, Directors He Yudong, Deng Qing, Wang Dong, and Vice President Yue Hongbo .
-
Yiling Pharmaceutical won the "Advanced Group for Poverty Alleviation in Hebei Province"
Time of Update: 2021-08-07
Corresponding poverty alleviation and assisting the construction of beautiful villages In terms of counterpart poverty alleviation, Yiling Pharmaceutical has successively invested more than 1 million yuan in infrastructure projects in poor villages .
-
Pfizer wins the copayment lawsuit!
Time of Update: 2021-08-07
CompilationFan DongdongLast summer, Pfizer was accused of helping patients participating in the medical insurance program pay for the expensive cardiac drugs Vyndaqel and Vyndamax by means of subsidies from patient charities, resulting in the payment of nearly $24 million in the federal settlement.
-
Qilu, Yuan Dong...Snatching 400 million anti-inflammatory and anti-rheumatic drugs, this Shandong pharmaceutical company enters the market
Time of Update: 2021-08-07
According to data from Meinenet, in 2020, the total sales of coxixib tablets in the terminals of public medical institutions in China and physical pharmacies in Chinese cities will exceed 400 million yuan, and Merck’s market share will exceed 90% .
-
To Biao Bayer!
Time of Update: 2021-08-07
0 Chinese Drug Evaluation DatabaseIn terms of consistency evaluation, Moxifloxacin Hydrochloride and Sodium Chloride Injection has been reviewed by 9 companies, of which 5 companies including Yangzijiang Pharmaceutical Group, Sichuan Kelun Pharmaceutical and Jiangsu Zhengda Fenghai Pharmaceutical have been approved for supplementary applications.
-
Due to controversy!
Time of Update: 2021-08-07
CompilationFan DongdongAs a controversial new drug for Alzheimer’s disease, one month after the approval of Biogen/Biogen’s Aduhelm, the US health regulatory agency updated the new prescription instructions for the drug’s restricted use on Thursday.
-
The original research drug soared by 374%!
Time of Update: 2021-08-07
0 Chinese Drug Evaluation DatabaseChengdu Better Pharmaceuticals has obtained approvals for 3 products in the field of diabetes medication, including Gliclazide tablets (Ⅱ), lipoic acid injection and metformin hydrochloride sustained-release tablets .
-
Yangtze River "overweights" 1 billion anti-epileptic drugs!
Time of Update: 2021-08-07
A few days ago, the official website of CDE showed that the Levetiracetam tablets of Nanjing Hailing Pharmaceutical of Yangtze River Pharmaceutical Group were accepted for the application of imitation 4 types of listing .
-
Amgen/BeiGene's new anti-cancer drug approved in China
Time of Update: 2021-08-07
In the subgroup of patients who received only one treatment with other therapies, KRd therapy was more effective, and compared with Rd therapy, it could prolong the average OS by 11.
-
Sichuan: Re-revision of Chinese medicine standards with 9 errata!
Time of Update: 2021-08-07
Medical Network, July 9 News On July 6, the Sichuan Provincial Food and Drug Administration issued a notice regarding corrections to nine Chinese medicine standards including madder .
-
Universal targeted drugs can reduce the risk of disease progression and death by 78%
Time of Update: 2021-08-07
Clinical trial results show that cabozantinib can significantly prolong the progression-free survival of radioiodine-refractory DTC patients who have previously received VEGFR-targeted therapy, and can significantly reduce the risk of disease progression or death .
-
Renhe Pharmaceutical won multiple companies for 719 million
Time of Update: 2021-08-07
It can be seen that in the first quarter of 2021, the national economy is generally stable, and the economic environment for the development of China's large-scale health industry is showing a good trend, and it has become a good choice for pharmaceutical companies to cross-border to the large-scale health field .
-
Hunan: 148 drugs including aluminum phosphate will stop reimbursement
Time of Update: 2021-08-07
148 drugs are transferred out of medical insuranceJuly 9, Hunan Medical Insurance Bureau released the "Notice on 2021 Hunan basic medical insurance, industrial injury insurance and maternity insurance digestive medicines adjustment period" .
-
The Food and Drug Administration is no longer entangled with millions of penalties, more in the future
Time of Update: 2021-08-07
After a year of entanglement, the Food and Drug Administration began to release itself, no longer entangled, millions of penalties came along with it, and large fines were flying like rain .
-
Hengrui Medicine passed the consistency evaluation of generic drugs for 6 drugs within 1 month
Time of Update: 2021-08-07
Medical Network News on May 8 Recently, Hengrui Pharmaceuticals received the "Drug Supplementary Application Approval Notice" approved and issued by the National Medical Products Administration, which approved the company's irinotecan hydrochloride injection and palonosetron hydrochloride injection to pass the imitation Consistency evaluation of pharmaceutical quality and efficacy .
-
Countdown to Cleanup of Local Medical Insurance Directory!
Time of Update: 2021-08-07
The former star drug of Jichuan Pharmaceutical is difficult to be removed by the local medical insurance catalogueThe former star drug of Jichuan Pharmaceutical is difficult to be removed by the local medical insurance catalogueOn July 6, Jichuan Pharmaceutical issued an announcement stating that the main varieties of Pudilan Anti-inflammatory Oral Liquid and Iron Protein Succinate Oral Solution, a wholly-owned subsidiary of Jichuan Pharmaceutical Group Co.
-
Four important points!
Time of Update: 2021-08-07
Medical Network, July 9th.
(Reporters Peng Yunjia and Mu Tiecheng; poster design: Yang Yiqun) Medical Network, July 9th.
(Reporters Peng Yunjia and Mu Tiecheng; poster design: Yang Yiqun)Medicine Medicine Medicine
-
Cinda's first small-molecule anti-cancer drug, pemigatinib tablet, applied for listing
Time of Update: 2021-08-06
On July 9th, Innovent announced that NMPA has officially accepted the application for the fibroblast growth factor receptor (FGFR) 1/2/3 inhibitor (pemigatinib tablet) for the market, for at least one systemic treatment in the past, and Adult patients with advanced, metastatic or unresectable cholangiocarcinoma with FGFR2 fusion or rearrangement confirmed by testing .
-
Baiyunshan amoxicillin capsule passed the consistency evaluation
Time of Update: 2021-08-06
The amoxicillin capsule of Baiyunshan Pharmaceutical General Factory was officially launched in China in August 2006, and the consistency evaluation application was submitted to the National Medical Products Administration on November 4, 2018, and it was accepted on November 12, 2018 .
